Monte Rosa Therapeutic (GLUE) Q2 2026 earnings summary

Executive summary

• Reported a net loss of $43.4 million for Q2 2026 and $87.9 million for the six months ended June 30, 2026, compared to net losses of $12.3 million and net income of $34.6 million for the same periods in 2025.

• Collaboration revenue declined sharply to $9.0 million in Q2 2026 from $23.2 million in Q2 2025, primarily due to lower upfront payments from partners.

• Operating expenses increased significantly, driven by higher R&D and G&A costs as the company advanced its clinical and preclinical pipeline.

• Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease risk; readout expected in H2 2026.

• Multiple Phase 2 studies for MRT-8102 and other programs planned or initiated from H2 2026 through H1 2027.

Financial highlights

• Q2 2026 collaboration revenue: $9.0 million, down from $23.2 million in Q2 2025.

• Q2 2026 operating expenses: $58.1 million, up from $38.7 million in Q2 2025; R&D expenses rose to $48.0 million.

• Net loss per share: $(0.43) basic and diluted for Q2 2026, compared to $(0.15) in Q2 2025.

• Cash, cash equivalents, restricted cash, and marketable securities totaled $626.0 million as of June 30, 2026, supporting operations into 2029.

• Completed a $345.0 million underwritten public offering in January 2026, netting $323.8 million.

Outlook and guidance

• Cash runway projected into 2029 based on current cash and marketable securities.

• Expects continued increases in R&D and G&A expenses as pipeline advances and clinical trials expand.

• Multiple Phase 2 studies for MRT-8102 to initiate in H2 2026 through H1 2027 across several indications.

• IND submissions for new programs planned for 2027.

• Additional funding will be required for future development and commercialization activities.